These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1594 related articles for article (PubMed ID: 28139362)

  • 1. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
    Sávolt A; Polgár C; Musonda P; Mátrai Z; Rényi-Vámos F; Tóth L; Kásler M; Péley G
    Clin Breast Cancer; 2013 Oct; 13(5):364-70. PubMed ID: 23773380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance.
    Youssef MMG; Cameron D; Pucher PH; Olsen S; Ferguson D
    Breast; 2016 Dec; 30():101-104. PubMed ID: 27668857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
    Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
    Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
    Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
    Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
    Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
    Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
    Houvenaeghel G; Cohen M; Raro P; De Troyer J; de Lara CT; Gimbergues P; Gauthier T; Faure-Virelizier C; Vaini-Cowen V; Lantheaume S; Regis C; Darai E; Ceccato V; D'Halluin G; Del Piano F; Villet R; Jouve E; Beedassy B; Theret P; Gabelle P; Zinzindohoue C; Opinel P; Marsollier-Ferrer C; Dhainaut-Speyer C; Colombo PE; Lambaudie E; Tallet A; Boher JM;
    BMC Cancer; 2018 Nov; 18(1):1153. PubMed ID: 30463611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
    Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different?
    Zakaria S; Pantvaidya G; Reynolds CA; Grant CS; Sterioff S; Donohue JH; Farley DR; Hoskin TL; Degnim AC
    Surgery; 2008 May; 143(5):641-7. PubMed ID: 18436012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000.
    Solá M; Alberro JA; Fraile M; Santesteban P; Ramos M; Fabregas R; Moral A; Ballester B; Vidal S
    Ann Surg Oncol; 2013 Jan; 20(1):120-7. PubMed ID: 22956062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of axillary recurrence in 344 sentinel node negative breast cancer patients after intermediate follow-up. A prospective study into the accuracy of sentinel node biopsy in breast cancer patients.
    Heuts EM; van der Ent FW; Hulsewé KW; Heeren PA; Hoofwijk AG
    Acta Chir Belg; 2007 Jun; 107(3):279-83. PubMed ID: 17685253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    Gingras I; Holmes E; De Azambuja E; Nguyen DH; Izquierdo M; Anne Zujewski J; Inbar M; Naume B; Tomasello G; Gralow JR; Wolff AC; Harris L; Gnant M; Moreno-Aspitia A; Piccart MJ; Azim HA
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy?
    Sanuki N; Takeda A; Amemiya A; Ofuchi T; Ono M; Ogata H; Yamagami R; Hatayama J; Eriguchi T; Kunieda E
    Clin Breast Cancer; 2013 Feb; 13(1):69-76. PubMed ID: 23062706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease recurrence in sentinel node-positive breast cancer patients forgoing axillary lymph node dissection.
    Cyr A; Gao F; Gillanders WE; Aft RL; Eberlein TJ; Margenthaler JA
    Ann Surg Oncol; 2012 Oct; 19(10):3185-91. PubMed ID: 22890591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
    de Boniface J; Appelgren M; Szulkin R; Alkner S; Andersson Y; Bergkvist L; Frisell J; Gentilini OD; Kontos M; Kühn T; Lundstedt D; Offersen BV; Olofsson Bagge R; Reimer T; Sund M; Christiansen P; Rydén L; Filtenborg Tvedskov T;
    Lancet Oncol; 2024 Sep; 25(9):1222-1230. PubMed ID: 39121881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
    Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
    Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
    Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
    Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
    Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
    Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.